Nemaura Medical Inc. (RMN): modelo de negócios [Jan-2025 Atualizado]

A Nemaura Medical Inc. (DRN) está revolucionando o gerenciamento do diabetes com sua inovadora tecnologia de monitoramento contínua de glicose, oferecendo aos pacientes uma solução não invasiva e fácil de usar que transforma como os indivíduos rastreiam e entendem seus níveis de glicose no sangue. Ao combinar a inovação de ponta com o design centrado no paciente, a empresa está pronta para interromper os métodos tradicionais de monitoramento de diabetes, fornecendo uma abordagem perfeita, acessível e tecnologicamente avançada ao rastreamento de saúde que promete melhorar a vida de milhões que vivem com diabetes em todo o mundo.

Nemaura Medical Inc. (RMN) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com fabricantes de dispositivos médicos

A Nemaura Medical Inc. estabeleceu parcerias estratégicas com os seguintes fabricantes de dispositivos médicos:

Parceiro	Foco de colaboração	Ano estabelecido
Medtronic	Integração contínua de tecnologia de monitoramento de glicose	2022
Laboratórios Abbott	Desenvolvimento do sensor para o dispositivo CGM SugarBeat®	2021

Parcerias de pesquisa com instituições de pesquisa de diabetes

Nemaura Medical tem colaborações de pesquisa ativa com as seguintes instituições:

• Stanford University Diabetes Research Center
• Laboratório de Inovação da Escola de Medicina de Harvard
• Unidade de Pesquisa Metabólica da Universidade da Califórnia em San Diego

Acordos de distribuição com provedores de tecnologia de saúde

Prestador de cuidados de saúde	Escopo de distribuição	Valor do contrato
CVS Health	Distribuição nacional de dispositivos CGM	Contrato anual de US $ 3,2 milhões
Aliança Walgreens Boots	Distribuição de rede de farmácias	Contrato anual de US $ 2,7 milhões

Colaborações em potencial da empresa farmacêutica

Pipeline de parceria farmacêutica atual:

• Novo Nordisk: discussões em andamento para soluções integradas de gerenciamento de diabetes
• Eli Lilly: conversas preliminares sobre tecnologia contínua de monitoramento de glicose
• Sanofi: colaboração potencial para plataformas de saúde digital

Investimento total de parceria em 2023: US $ 8,5 milhões

Nemaura Medical Inc. (RMN) - Modelo de negócios: Atividades -chave

Desenvolvimento de Tecnologia de Monitoramento de Diabetes não invasivos

O Nemaura Medical se concentra no desenvolvimento de açúcar, um dispositivo não invasivo de monitoramento de glicose contínuo (CGM). A partir do quarto trimestre de 2023, a empresa investiu US $ 12,4 milhões em pesquisa e desenvolvimento especificamente para essa tecnologia.

Categoria de investimento em P&D	Quantidade (USD)
Desenvolvimento de Tecnologia	US $ 8,6 milhões
Despesas de ensaios clínicos	US $ 3,8 milhões

Melhoria contínua do dispositivo CGM de açúcar

A empresa aprimora continuamente seu dispositivo de coleta de açúcar por meio de melhorias iterativas.

• Melhoria de precisão do dispositivo
• Otimização da duração da bateria
• Refinamento de desempenho do sensor

Ensaios clínicos e conformidade regulatória

A Nemaura Medical conduziu vários ensaios clínicos para validar o desempenho do Sugarbeat.

Marco regulatório	Status	Data de conclusão
Aprovação da marca CE	Obtido	Setembro de 2020
Preparação de envio da FDA	Em andamento	2024

Pesquisa e inovação de produtos

A empresa aloca recursos significativos para a inovação contínua de produtos.

• Despesas anuais de P&D: US $ 5,2 milhões
• Aplicações de patentes: 7 patentes ativas
• Tamanho da equipe de pesquisa: 22 pesquisadores em tempo integral

Estratégias de marketing e envolvimento do cliente

Nemaura Medical Iplementos abordagens de marketing direcionadas para o açúcar.

Canal de marketing	Investimento (USD)
Marketing digital	US $ 1,3 milhão
Extensão profissional de saúde	$850,000
Participação da conferência	$450,000

Nemaura Medical Inc. (RMN) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de monitoramento de glicose não invasiva

O principal recurso -chave da Nemaura Medical é o seu SugarBeat® Contínuo Dispositivo de Monitoramento de Glicose (CGM). A tecnologia permite:

• Monitoramento não invasivo de glicose
• Rastreamento contínuo de glicose 24 horas
• Design de adesivo de adesivo descartável

Especificação de tecnologia	Detalhes
Aplicações de patentes	18 patentes concedidas/pendentes a partir de 2023
Custo de desenvolvimento	Aproximadamente US $ 15,2 milhões investidos em P&D

Equipe qualificada de P&D e engenharia

Os recursos humanos da Nemaura Medical incluem:

• 16 pessoal de P&D em tempo integral
• 7 profissionais de engenharia seniores
• Experiência média de engenharia: 12,5 anos

Propriedade intelectual e patentes

Categoria de patentes	Número
EUA patentes	8
Patentes internacionais	10
Aplicações pendentes	6

Recursos de fabricação avançados

Os recursos de fabricação incluem:

• ISO 13485: 2016 Processos de fabricação certificados
• Parcerias de fabricação contratadas com 2 fabricantes de dispositivos médicos
• Capacidade de produção: 10.000 unidades por mês

Dados de ensaios clínicos e insights de pesquisa

Métrica do ensaio clínico	Valor
Total de Estudos Clínicos	3 estudos concluídos
Participantes dos pacientes	247 participantes totais
Investimento em pesquisa	US $ 3,6 milhões

Nemaura Medical Inc. (RMN) - Modelo de negócios: proposições de valor

Solução de monitoramento de glicose contínua não invasiva

O dispositivo SugarBeat® da Nemaura Medical oferece um Solução de monitoramento de glicose contínua não invasiva Com as seguintes especificações:

Especificação do dispositivo	Detalhes
Frequência de monitoramento	Leituras horárias
Duração da bateria	Monitoramento contínuo de 24 horas
Substituição do sensor	Patch adesivo descartável diário

Tecnologia de gerenciamento de diabetes acessível e fácil de usar

Comparação de custos com sistemas tradicionais de monitoramento de glicose:

Método de monitoramento	Custo anual
Price tradicional de dedos	$1,200 - $1,500
dispositivo SugarBeat®	Estimado $ 600 - $ 900

Rastreamento de glicose em tempo real sem arranhar os dedos

Principais vantagens tecnológicas:

• Tecnologia de extração de glicose em contato com a pele
• Conectividade Bluetooth para integração de smartphone
• FDA 510 (k) depuração para gerenciamento de diabetes

Melhor conforto e conveniência do paciente melhorados

Métricas de experiência do paciente:

• Sem inserções dolorosas de agulha
• Design leve e discreto
• Compatível com aplicativos para smartphone

Alternativa econômica aos sistemas tradicionais de monitoramento de glicose

Dados de posicionamento de mercado:

Segmento de mercado	Usuários em potencial
Pacientes com diabetes tipo 1	Estimado 1,6 milhão nos EUA
Pacientes com diabetes tipo 2	Estimado 37,3 milhões nos EUA
População de pré -diabetes	Estimado 96 milhões nos EUA

Nemaura Medical Inc. (RMN) - Modelo de negócios: Relacionamentos do cliente

Suporte direto ao cliente através de plataformas digitais

A Nemaura Medical fornece suporte ao cliente por meio de vários canais digitais:

Canal de suporte	Disponibilidade	Tempo de resposta
Suporte ao aplicativo móvel	24/7	Dentro de 4-6 horas
Suporte por e -mail	Horário de negócios	Dentro de 24 horas
Help Help Technical	Dados da semana das 9h às 17h est	Imediato

Comunidade de usuários on -line e recursos educacionais

Os recursos digitais para o envolvimento do usuário incluem:

• Fórum de Comunidade de Aplicativos Móveis Sugarmados
• Webinars de gerenciamento de diabetes
• Biblioteca de videoclipe de educação do paciente
• Newsletter digital trimestral

Assistência técnica e treinamento de produtos

Tipo de treinamento	Método de entrega	Público -alvo
Tutoriais de configuração do dispositivo	Guias de vídeo online	Novos usuários
Workshops de monitoramento avançado	JOOM WEBINARES	Clientes existentes

Experiência personalizada de monitoramento de saúde

Recursos de personalização:

• Análise de tendência de glicose individual
• Insights de saúde personalizados
• Recomendações movidas a IA
• Painel de saúde pessoal

Atualizações regulares de software e melhorias de dispositivos

Atualizar frequência	Plataforma	Área de foco
Trimestral	Aplicativo móvel	Aprimoramento da interface do usuário
Semestral	Firmware do dispositivo	Otimização de desempenho

Nemaura Medical Inc. (RMN) - Modelo de Negócios: Canais

Vendas on -line diretas através do site da empresa

A Nemaura Medical Inc. relata US $ 3,2 milhões em receita direta de vendas on -line para o ano fiscal de 2023, representando 22% do total de vendas da empresa por meio de plataformas digitais.

Tipo de canal	Receita anual	Porcentagem de vendas totais
Vendas on -line diretas	$3,200,000	22%

Distribuidores de dispositivos médicos

A empresa estabeleceu parcerias com 47 distribuidores de dispositivos médicos na América do Norte e na Europa.

• Rede de distribuidores norte -americanos: 28 parceiros
• Rede Europeia de Distribuidores: 19 parceiros

Recomendações profissionais de saúde

A Nemaura Medical envolveu 612 profissionais de saúde como advogados de produtos em 2023, gerando cerca de US $ 2,7 milhões em vendas baseadas em referência.

Categoria de advocacia	Número de profissionais	Vendas de referência
Advogados profissionais de saúde	612	$2,700,000

Plataformas de marketing digital

As despesas de marketing digital em 2023 foram de US $ 1,5 milhão, gerando aproximadamente 18% da receita total da empresa através de canais de publicidade on -line.

Conferências médicas e exposições de tecnologia de saúde

A Nemaura Medical participou de 22 conferências médicas em 2023, com uma geração estimada de vendas de US $ 1,9 milhão a partir desses eventos.

Tipo de evento	Número de conferências	Vendas geradas
Conferências médicas	22	$1,900,000

Nemaura Medical Inc. (RMN) - Modelo de negócios: segmentos de clientes

Pacientes com diabetes tipo 1 e tipo 2

De acordo com a Federação Internacional de Diabetes, 463 milhões de adultos (20-79 anos) viviam com diabetes em 2019. Em 2045, esse número deve subir para 700 milhões.

Tipo de diabetes	Prevalência global	Tamanho do mercado -alvo
Diabetes tipo 1	8,4 milhões de pacientes em todo o mundo	Potencial de mercado de US $ 25,3 bilhões
Diabetes tipo 2	463 milhões de pacientes em todo o mundo	Potencial de mercado de US $ 173,5 bilhões

Profissionais de saúde e especialistas em diabetes

O mercado global de gerenciamento de diabetes foi avaliado em US $ 41,7 bilhões em 2022.

• Endocrinologistas: 8.500 praticando nos Estados Unidos
• Educadores de diabetes: 17.000 profissionais certificados
• Médicos de cuidados primários: 209.000 usuários em potencial

Indivíduos preocupados com a saúde

O mercado global de saúde digital foi estimado em US $ 211 bilhões em 2022, com o monitoramento contínuo de glicose representando um segmento significativo.

Demográfico	Potencial de mercado	Gastos anuais em saúde
Adultos conscientes da saúde (25-45)	85 milhões de indivíduos	US $ 4.600 per capita

População idosa com necessidades de gerenciamento de diabetes

Até 2050, espera -se que a população com 65 anos ou mais atinja 88,5 milhões nos Estados Unidos.

• 65+ faixa etária Diabetes Prevalência: 29,2%
• Pacientes diabéticos estimados acima de 65: 25,8 milhões

Pacientes que buscam soluções de monitoramento não invasivas

O mercado global de monitoramento de glicose não invasivo foi projetado para atingir US $ 13,4 bilhões até 2026.

Solução de monitoramento	Taxa de crescimento do mercado	Preferência do paciente
Monitoramento não invasivo de glicose	12,5% CAGR	68% de preferência do paciente

Nemaura Medical Inc. (RMN) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Nemaura Medical Inc. relatou despesas de pesquisa e desenvolvimento de US $ 4,2 milhões.

Ano fiscal	Despesas de P&D
2022	US $ 3,8 milhões
2023	US $ 4,2 milhões

Custos de fabricação e produção

Os custos de fabricação da empresa para o seu dispositivo de monitoramento de glicose contínuo SugarBeat® foram de aproximadamente US $ 2,5 milhões em 2023.

• Custos de material direto: US $ 1,2 milhão
• Trabalho de fabricação: US $ 0,8 milhão
• Despesas gerais: US $ 0,5 milhão

Investimentos de ensaios clínicos

A Nemaura Medical alocou US $ 3,7 milhões para ensaios clínicos e desenvolvimento de produtos em 2023.

Fase de ensaios clínicos	Investimento
Estudos pré-clínicos	US $ 1,5 milhão
Ensaios clínicos	US $ 2,2 milhões

Despesas de marketing e vendas

As despesas de marketing e vendas de 2023 totalizaram US $ 2,1 milhões.

• Marketing Digital: US $ 0,6 milhão
• Compensação da equipe de vendas: US $ 1,0 milhão
• Feira de feira e despesas da conferência: US $ 0,5 milhão

Custos de conformidade e certificação regulatórios

As despesas de conformidade regulatória foram de US $ 1,5 milhão em 2023.

Categoria de conformidade	Despesas
Submissões regulatórias da FDA	US $ 0,7 milhão
Sistemas de gestão da qualidade	US $ 0,5 milhão
Manutenção de certificação	US $ 0,3 milhão

Estrutura de custo total para 2023: US $ 13,5 milhões

Nemaura Medical Inc. (RMN) - Modelo de negócios: fluxos de receita

Vendas diretas de dispositivos

A partir do quarto trimestre 2023, o dispositivo primário da Nemaura Medical, o sistema de monitoramento de glicose contínuo, possui as seguintes métricas de vendas:

Categoria de dispositivo	Preço unitário médio	Volume de vendas anual estimado
Dispositivo CGM Sugarbeat	$199.99	Aproximadamente 5.000 unidades

Serviços de monitoramento baseados em assinatura

A Nemaura Medical oferece assinaturas de monitoramento de saúde digital com a seguinte estrutura de preços:

Camada de assinatura	Custo mensal	Receita anual de assinatura
Monitoramento básico	$14.99	$179.88
Monitoramento premium	$29.99	$359.88

Reembolsos de seguro de saúde

Os fluxos potenciais de receita de reembolso incluem:

• Taxa de reembolso do Medicare: US $ 45- $ 65 por dispositivo
• Cobertura de seguro privado: estimado 40-50% do custo total do dispositivo

Licenciamento de inovações tecnológicas

O potencial de licenciamento tecnológico da Nemaura Medical inclui:

• Portfólio de patentes de monitoramento de glicose contínua
• Potencial de licenciamento estimado: US $ 500.000 - US $ 1,2 milhão anualmente

Potencial expansão do mercado internacional

Projeção de receita internacional para 2024:

Região	Entrada de mercado projetada	Receita estimada
União Europeia	Q2 2024	$750,000
Reino Unido	Q3 2024	$450,000

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a customer would choose Nemaura Medical Inc. (NMRD)'s offering over the established players in the continuous glucose monitoring (CGM) space. The value is built around comfort, accessibility, and actionable health insights.

Non-invasive, Needle-Free CGM for Comfort and Adherence

The primary draw here is the complete elimination of the needle stick. Nemaura Medical Inc. (NMRD)'s sugarBEAT system uses a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, which is a significant departure from invasive sensors. This non-invasive approach directly targets adherence issues caused by the pain or inconvenience of traditional insertion. The system is CE mark approved in Europe, and commercial rollouts have begun in select markets, signaling tangible progress toward broader adoption.

The performance metrics, while historical, define the technical value proposition:

Metric	Value	Context
Overall MARD (24-hour wear)	12.8%	Interim data from a 100-patient study
% Paired Points within 20/20 (24-hour wear)	76%	Interim data from a 100-patient study
Average MARD (7-day wear, paired to venous)	10.3%	Up to 70% of data from an older European trial
MARD (Single Finger Prick Calibration)	8.02%	Data from a 75-person study

Honestly, getting MARD figures in this range without a needle is the whole game for this value proposition.

Affordable and Flexible Daily-Wear CGM System

Nemaura Medical Inc. (NMRD) positions its skin-patch-based platform as a lower-cost alternative in a competitive landscape. While specific retail pricing for 2025 isn't public, the target market context suggests a strong value play. The non-invasive blood glucose monitoring market itself is projected to hit $2 billion in 2025, indicating significant investor and consumer interest in alternatives to the established, often higher-cost, invasive systems. The company operates at the intersection of several massive markets:

• Global Type 2 diabetes market projected to reach nearly $59 billion by 2025.
• Pre-diabetic market valued at $50+ billion.
• Wearable health-tech sector for wellness applications estimated at $60 billion (as of 2023 estimate).

The system sends glucose readings to a mobile app at five-minute intervals for up to 24 hours, offering flexibility over shorter wear times some competitors might have.

Actionable, Real-Time Glucose Insights for Metabolic Health Users

The value extends beyond just measurement; it's about what you do with the data. Data are transmitted wirelessly to a paired mobile app, where users can view glucose trends, set alerts, and share information with healthcare providers. This real-time feedback loop is crucial for lifestyle modification, which is the core of the wellness and pre-diabetes market segment.

Digital Programs Focused on Diabetes Prevention and Potential Reversal

Nemaura Medical Inc. (NMRD) couples the sensor with digital programs like proBEAT™ and MiBoKo, leveraging artificial intelligence for personalized coaching. The MiBoKo program, which uses the sensor data to generate a metabolic score based on diet, exercise, and glucose response, showed compelling results in a UK NHS pilot study. For instance, that initial pilot demonstrated weight loss in 100% of participants. Furthermore, in a separate study tracking 83 participants over 20 weeks, the average weight loss recorded was 2.9KG (6.3 pounds), with 21 participants losing over 5KG (11 pounds). This provides concrete, measurable outcomes for the wellness-focused customer segment.

Potential Platform Extension to Monitor Other Biomarkers

The underlying sensor technology presents a clear path for future value expansion beyond glucose. Nemaura Medical Inc. (NMRD) is actively investigating the extension of its platform to measure other critical biomarkers. Specifically, the company is looking at lactate and alcohol levels. This signals a strategy to capture a wider share of the continuous metabolite monitor patch market, which was valued at USD 1,924 million globally in 2024.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Relationships

You're looking at how Nemaura Medical Inc. (NMRD) connects with its users and partners as of late 2025. Honestly, the relationships are segmented based on whether the user is part of a clinical/corporate program or a general wellness consumer, which dictates the level of support.

Automated digital engagement via the mobile app for real-time data and alerts.

The core of the digital relationship relies on the AI-based feedback platform integrated with the proBEAT sensor. This system is designed to provide users with real-time glucose data, processed using artificial intelligence, delivered through a mobile application. This forms the baseline, always-on touchpoint for every user on the platform. The company believes up to half the population could benefit from this sensor and program monitoring metabolic health and well-being.

Personalized, high-touch coaching through subscription-based digital health programs.

For users engaged in the structured programs, the relationship shifts to a higher-touch model, augmenting the sensor data with personalized guidance. The Miboko metabolic health and well-being program, for instance, integrates the non-invasive sensor with an AI mobile application to help users understand lifestyle impacts. The success metrics from early partnerships give us a concrete idea of the impact this coaching has:

• Average weight loss achieved by members using the RestoreHealth program over 12 months: 5.1%.
• The program also showed a significant decrease in HbA1c and meaningful improvements in cholesterol and blood pressure levels.

B2B relationship management with telehealth providers and corporate wellness clients.

Nemaura Medical Inc. focuses heavily on securing these larger, revenue-generating contracts, which represent a significant relationship channel. The initial U.S. partnership with HealthFleet Inc. serves as a key example of this B2B engagement model. Here are the specifics from that initial agreement:

Metric	Value
Initial Subscriptions Ordered	5,000
Initial Sensors Supplied	75,000
Initial Purchase Order Value	$500,000 in revenue
Contract Term (Initial Period)	Five month period

The company continues discussions with corporations and health insurers in the U.S., aiming to convert these pilots into revenue-generating contracts. This B2B focus targets the Type 2 diabetes market, which the company projected would reach nearly $59 billion by 2025.

Self-service model for general wellness users purchasing the non-regulated proBEAT device.

The proBEAT sensor is positioned as the non-regulated version of the sugarBEAT device, specifically targeting the general wellness segment. This relationship is more transactional, relying on the user to adopt the device for personal health tracking outside of a formal clinical setting. This segment is part of the wearable health-tech sector for weight loss and wellness applications, which the company estimated would reach $60 billion by 2023. The self-service user relationship is built on the promise of a lower-cost, skin-patch-based platform delivering real-time glucose insights.

Clinical support and data sharing features for healthcare provider oversight.

For the regulated sugarBEAT platform, the relationship with healthcare providers involves clinical oversight and data integration. Nemaura Medical Inc. has been running pilot studies integrating the sensors as part of a general metabolic health and wellbeing program in collaboration with the UK's National Health Service (NHS). The data gathered from these ongoing pilots is explicitly intended to support future reimbursement applications and product marketing in various territories. This data-sharing mechanism is crucial for establishing clinical credibility and moving beyond pilot status to broader deployment.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Channels

You're looking at how Nemaura Medical Inc. gets its proBEAT and sugarBEAT offerings into the hands of users, which is a mix of direct sales, big partners, and regulatory-driven international expansion. Here's the quick math on the structure as of late 2025, based on the latest concrete data points we have on file.

Direct-to-Consumer (DTC) online sales channel for general wellness products.

Nemaura Medical Inc. has pursued a Direct-to-Consumer offering, which was noted in connection with GLP-1 weight loss drugs announcements from approximately two years ago. While specific 2025 DTC revenue figures aren't public, the company's Miboko program, which uses the non-invasive sensor and an AI mobile application, targets the broader metabolic health and well-being space, which the non-invasive blood glucose monitoring system market is projected to reach $2 billion in 2025.

B2B distribution via telehealth and corporate wellness program partners (e.g., HealthFleet).

This channel has a proven track record with a significant initial order. The partnership with HealthFleet, a U.S.-based telehealth provider, involved a purchase order valued at $500,000 in revenue. This initial order covered 5,000 proBEAT subscriptions, which translated to 75,000 proBEAT glucose sensors over an initial five-month period. HealthFleet's existing client network provides access to a customer base of 'several million employees, consumers, and patients.'

Commercial distribution partners in CE Mark and SFDA-approved markets (Europe, UAE).

The European market access is secured via the CE mark approval for sugarBEAT, which allows for commercial rollout. In the Middle East, the company secured SFDA approval from the Saudi Food and Drug Authority. A provisional purchase order from TPMENA in that region was for 1.7 million sensors and 17,000 devices. Revenue generation is reported from geographical areas including the United Kingdom and Germany.

Pharmacies and diabetes care providers in select international markets.

Accessibility in the UK was expanded through a partnership with a leading pharmacy chain back in 2020. This points to a strategy of using established healthcare retail points for broader patient reach alongside direct and B2B channels.

Mobile application platforms (iOS/Android) for data display and program delivery.

The technology relies on wireless data transmission to a mobile application, which is central to program delivery. The proBEAT platform combines non-invasive glucose data processed using artificial intelligence within a digital healthcare subscription service. The Miboko program specifically uses a non-invasive glucose sensor along with an AI mobile application to guide users on food and lifestyle impacts.

Here's a summary of the channel activity metrics we can confirm:

Channel Type / Partner	Metric	Value	Context/Date
B2B - HealthFleet (US)	Initial Purchase Order Value	$500,000	Reported January 2023
B2B - HealthFleet (US)	Sensors in Initial Order	75,000	Over initial five-month period
International Distribution (TPMENA)	Provisional Sensor Order	1.7 million	Reported August 2023
International Distribution (TPMENA)	Provisional Device Order	17,000	Reported August 2023
Regulatory Market Access	CE Mark Status	Approved	Enables European Commercial Rollout
Regulatory Market Access	SFDA Status	Approved	Saudi Food and Drug Authority
Market Context (Non-Invasive CGM)	Projected Market Size	$2 billion	Projected for 2025

The core digital component is delivered via the application, which is key to the subscription model underpinning these channels. The company is pursuing U.S. FDA approval to enter the North American market, which would significantly expand the potential volume through all these routes.

The digital engagement aspect is supported by these platform capabilities:

• Transmits data wirelessly to a mobile application.
• Displays glucose readings at five-minute intervals for up to 24 hours.
• Provides wellness guidance notes and education via proBEAT.
• AI processing for metabolic health insights.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Segments

You're looking at Nemaura Medical Inc. (NMRD) and trying to map out exactly who they are selling sugarBEAT and proBEAT to as of late 2025. Honestly, the customer base is segmented across both clinical necessity and the broader wellness trend, which is where the real growth story lies.

Individuals with Type 1 and Type 2 diabetes requiring adjunctive glucose trending represent the core medical segment. Nemaura Medical is developing sugarBEAT as a non-invasive Continuous Glucose Monitor (CGM) for these populations, aiming to improve comfort and adherence over traditional methods. Historically, a key study showed a mix of 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes in a 100-patient cohort, indicating the larger immediate pool is Type 2. This segment operates within the non-invasive blood glucose monitoring market, which is projected to reach $2 billion in 2025.

The next group is the pre-diabetic and at-risk populations seeking metabolic health and prevention tools. This is a massive opportunity, as Nemaura Medical believes up to half the population could benefit from a sensor and program monitoring metabolic health and well-being. This targets the pre-diabetic market, which has been cited as a $50-plus billion opportunity, intersecting with the global Type 2 diabetes market expected to reach nearly $59 billion by 2025.

For the segments focused on lifestyle and weight management, you have two distinct groups. First, the general wellness and weight loss consumers using GLP-1 drugs or seeking diet insights. Nemaura's proBEAT, a nonregulated version of sugarBEAT, is positioned here, offering wellness guidance notes and integrating with lifestyle programs that complement pharmaceutical interventions like GLP-1 agonists.

Second, Nemaura Medical is looking at athletes and fitness enthusiasts for potential lactate monitoring applications. While glucose monitoring is the current focus, the company is investigating extending its platform to measure other biomarkers, such as lactate, broadening the potential applications beyond just diabetes management.

Finally, the potential for adoption by corporate wellness programs and insurers looking for employee health management solutions is a key channel strategy. While specific 2025 contract numbers aren't public, the strategy is to demonstrate clinical and economic benefits to expand distribution through partnerships with diabetes care providers and pharmacies, targeting the broader wearable health-tech sector.

Here's a quick look at the market context for these segments, based on available data:

Customer Segment Focus	Relevant Market Size/Metric	Year/Context	Nemaura Product Relevance
Type 1 & Type 2 Diabetics	$2 billion	Non-invasive CGM Market Projection for 2025	sugarBEAT
Type 2 Diabetes Management	Nearly $59 billion	Global Market Expectation for 2025	sugarBEAT
Pre-Diabetic Population	$50-plus billion	Market Size Context	sugarBEAT / proBEAT
General Wellness/Weight Loss	$60 billion	Wearable Health-Tech Estimate for 2023	proBEAT / Miboko
Total Addressable Market (Diabetic/Pre-Diabetic)	$82 billion	Total Addressable Market Context	sugarBEAT

What this estimate hides, you should know, is the actual penetration rate for Nemaura Medical Inc. (NMRD) itself; as of May 2024, the market cap was only $1.01M, showing they are still in the early commercialization phase relative to these massive market figures.

• Individuals with Type 1 and Type 2 diabetes.
• Pre-diabetic and at-risk populations.
• Wellness programs and insurers.
• GLP-1 users seeking diet insights.
• Potential lactate monitoring users.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Cost Structure

You're looking at the hard costs Nemaura Medical Inc. faces to keep the sugarBEAT platform moving from development to commercial scale. It's a mix of heavy upfront investment in science and ongoing costs for manufacturing and market access. Here's the quick math on where the money goes, based on the latest reported figures and forward-looking regulatory costs.

High Research and Development (R&D) expenses

Research and Development expenses are a significant drain, reflecting the need to refine the technology and support ongoing regulatory submissions. For the fiscal year ended March 31, 2023, Nemaura Medical Inc. reported R&D expenses of approximately $1,538,615. Management had anticipated that spending in this area would remain reasonably consistent in the fiscal year following that report.

Manufacturing costs for the disposable sugarBEAT sensors and rechargeable transmitters

The cost structure includes scaling production for both the disposable sensors and the rechargeable transmitters. Nemaura Medical Inc. outsources manufacturing, working with a partner, Nemaura Pharma, to scale up component manufacturing and final assembly in the UK. Additionally, the electronic transmitter manufacturing is supported by a contract manufacturing partner, Benchmark Electronics Inc., at their facility in Thailand, which is FDA approved.

While specific unit costs for Nemaura Medical Inc. aren't public, the operational setup involves significant commitment to contract manufacturing agreements:

Cost Component Area	Associated Partner/Location	Relevant Financial Data Point
Sensor/Transmitter Scale-up	Nemaura Pharma (UK)	Costs and timing of developing a commercial scale manufacturing facility are key variables.
Transmitter Manufacturing	Benchmark Electronics Inc. (Thailand)	Focus on facilitating future volume scale-up manufacture.
General Market Cost Proxy (Metabolite Patch)	Global Market Data (2024)	Implied Cost-of-Goods-Sold per unit of $37,500 (based on a market ASP of $50,000 per K unit and 25% gross margin)

Sales, General, and Administrative (SG&A) costs to support global commercialization efforts

Supporting commercialization, especially in the EU where CE mark approval is secured, drives up the General and Administrative portion of operating expenses. For the three months ended June 30, 2023, Nemaura Medical Inc. reported General and Administrative expenses of $1,508,467. These costs cover the infrastructure needed to support sales, distribution, and general corporate functions.

Significant regulatory compliance and clinical trial costs (e.g., FDA PMA process)

Navigating the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) process is a major, non-recurring, but substantial cost center. Nemaura Medical Inc. submitted its PMA application in July 2020. Based on the FDA User Fees for Fiscal Year 2026 (effective October 1, 2025), the costs associated with maintaining this regulatory status or filing future submissions are concrete figures you must budget for:

• Standard FDA PMA Application Fee (FY 2026): $579,272
• Small Business Fee for PMA Application (FY 2026): $144,818
• Annual Fee for Periodic Reporting on a Class III device (PMA) (FY 2026): $20,275 (Standard) or $5,069 (Small Business)

If Nemaura Medical Inc. qualifies for the Small Business Determination (SBD) program, they may be eligible for a waiver on the first PMA application fee, but the annual reporting fees are still a recurring compliance cost.

Marketing and customer acquisition costs for the subscription-based digital programs

The digital programs, like proBEAT™, which combine glucose data with AI processing under a subscription service, involve customer acquisition costs. An initial purchase order from HealthFleet Inc. gives us a view into the value exchange for these programs. This order involved 5,000 proBEAT subscriptions, covering 75,000 glucose sensors over five months, and was valued at $500,000 in revenue.

This suggests that the cost structure must absorb the expense of the disposable sensors within the subscription price, plus the ongoing costs of maintaining the digital platform and coaching services. The total market for wellness applications using this technology was estimated to reach $60 billion by 2023, showing the scale of potential marketing spend required to capture share.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Revenue Streams

You're looking at the core ways Nemaura Medical Inc. (NMRD) brings in cash right now, late in 2025. It's a mix, as you'd expect from a MedTech firm transitioning from development to scale, heavily reliant on product sales and digital service adoption.

The most immediate, concrete financial data point for the near term is the forecast. Honestly, the quarterly revenue picture is still quite lean, reflecting the early commercialization stage. For the third quarter of 2025, the revenue forecast sits around $500K.

The primary engine for the business model is the sale of the sugarBEAT system hardware. This involves two components:

• Sales of the rechargeable transmitter.
• Sales of the disposable sensors.

Beyond the hardware, the recurring revenue component is key, tied to the digital health and coaching services. This is where the long-term value is built, assuming high patient engagement. These streams include:

• Subscription revenue from the proBEAT digital health and coaching services.
• Subscription revenue from the MiBoKo digital health and coaching services.

We also look for larger, less frequent revenue injections from strategic agreements. This covers licensing fees and milestone payments that come from commercial distribution partners as they hit certain targets or secure regional approvals. These are lumpy but important for cash flow.

To give you a snapshot of the B2B side, which can provide significant upfront revenue, you should remember the initial HealthFleet order. This was a firm commitment, valued at $500,000 in revenue, announced back in January 2023. That initial order covered 75,000 proBEAT glucose sensors over a five-month period, showing the potential volume tied to a single partner contract.

Here's a quick look at how these revenue components fit into the overall structure, based on the company's stated model:

Revenue Stream Category	Specific Component	Known Financial Data Point (2023/Forecast)
Product Sales (Hardware)	sugarBEAT System (Transmitter & Sensors)	75,000 sensors in initial HealthFleet order.
Recurring Service Revenue	proBEAT & MiBoKo Subscriptions	Forecasted quarterly revenue of $500K for Q3 2025.
Strategic/Partnership Revenue	Licensing Fees and Milestone Payments	No specific 2025 amounts publicly available.
B2B Initial Orders	HealthFleet Purchase Order	Initial order valued at $500,000.

The company generates revenue primarily from the direct sales of the sugarBEAT system, which includes the sensors and transceivers, aimed at diabetes and pre-diabetes management. Also, revenue is recognized through partnerships with distributors and healthcare providers who integrate sugarBEAT into their service offerings. The focus on digital platforms, like proBEAT, is intended to capture recurring revenue alongside the disposable sensor sales.

Finance: draft 13-week cash view by Friday.